These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35362055)

  • 1. Association Between Procalcitonin and Antibiotics in Children With Community-Acquired Pneumonia.
    Sekmen M; Johnson J; Zhu Y; Sartori LF; Grijalva CG; Stassun J; Arnold DH; Ampofo K; Robison J; Gesteland PH; Pavia AT; Williams DJ
    Hosp Pediatr; 2022 Apr; 12(4):384-391. PubMed ID: 35362055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic stewardship: Early discontinuation of antibiotics based on procalcitonin level in COVID-19 pneumonia.
    Roy A; Powers HR; Craver EC; Nazareno MD; Yarrarapu SNS; Sanghavi DK
    J Clin Pharm Ther; 2022 Feb; 47(2):243-247. PubMed ID: 34766357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia.
    Stockmann C; Ampofo K; Killpack J; Williams DJ; Edwards KM; Grijalva CG; Arnold SR; McCullers JA; Anderson EJ; Wunderink RG; Self WH; Bramley A; Jain S; Pavia AT; Blaschke AJ
    J Pediatric Infect Dis Soc; 2018 Feb; 7(1):46-53. PubMed ID: 28158460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia.
    Esposito S; Tagliabue C; Picciolli I; Semino M; Sabatini C; Consolo S; Bosis S; Pinzani R; Principi N
    Respir Med; 2011 Dec; 105(12):1939-45. PubMed ID: 21959024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19).
    Fabre V; Karaba S; Amoah J; Robinson M; Jones G; Dzintars K; Katz M; Landrum BM; Qasba S; Gupta P; Klein E; Cosgrove SE
    Infect Control Hosp Epidemiol; 2022 May; 43(5):570-575. PubMed ID: 33866995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia.
    Long W; Deng X; Zhang Y; Lu G; Xie J; Tang J
    Respirology; 2011 Jul; 16(5):819-24. PubMed ID: 21507143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procalcitonin-Guided Antibiotic Discontinuation Might Shorten the Duration of Antibiotic Treatment Without Increasing Pneumonia Recurrence.
    Akagi T; Nagata N; Wakamatsu K; Harada T; Miyazaki H; Takeda S; Ushijima S; Aoyama T; Yoshida Y; Yatsugi H; Wada K; Ueda Y; Fujita M; Watanabe K
    Am J Med Sci; 2019 Jul; 358(1):33-44. PubMed ID: 31084909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad- versus Narrow-Spectrum Oral Antibiotic Transition and Outcomes in Health Care-associated Pneumonia.
    Buckel WR; Stenehjem E; Sorensen J; Dean N; Webb B
    Ann Am Thorac Soc; 2017 Feb; 14(2):200-205. PubMed ID: 27690519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procalcitonin predicts response to beta-lactam treatment in hospitalized children with community-acquired pneumonia.
    Cohen JF; Leis A; Lecarpentier T; Raymond J; Gendrel D; Chalumeau M
    PLoS One; 2012; 7(5):e36927. PubMed ID: 22615848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial.
    Masiá M; Padilla S; Ortiz de la Tabla V; González M; Bas C; Gutiérrez F
    PLoS One; 2017; 12(4):e0175634. PubMed ID: 28426811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic Choice and Clinical Outcomes in Ambulatory Children with Community-Acquired Pneumonia.
    Lipsett SC; Hall M; Ambroggio L; Hersh AL; Shah SS; Brogan TV; Gerber JS; Williams DJ; Grijalva CG; Blaschke AJ; Neuman MI
    J Pediatr; 2021 Feb; 229():207-215.e1. PubMed ID: 33045236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
    Lindstrom ST; Wong EK
    Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic value of serum procalcitonin in identifying the etiology of non-responding community-acquired pneumonia after initial antibiotic therapy].
    Wang Z; Zhang X; Wu J; Zhang W; Kuang H; Li X; Xuan W; Wang K; Ma L
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Nov; 37(11):824-30. PubMed ID: 25604112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient].
    Long W; Deng XQ; Tang JG; Xie J; Zhang YC; Zhang Y; Gao YY; Lu G
    Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):216-9. PubMed ID: 19576090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.
    Schuetz P; Müller B; Christ-Crain M; Stolz D; Tamm M; Bouadma L; Luyt CE; Wolff M; Chastre J; Tubach F; Kristoffersen KB; Burkhardt O; Welte T; Schroeder S; Nobre V; Wei L; Bhatnagar N; Bucher HC; Briel M
    Evid Based Child Health; 2013 Jul; 8(4):1297-371. PubMed ID: 23877944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of serum procalcitonin for the guidance of antibiotic therapy in children with lower respiratory tract infection].
    Dai BQ; Yuan XT; Liu JM
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Dec; 17(12):1292-6. PubMed ID: 26695667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.
    Westwood M; Ramaekers B; Whiting P; Tomini F; Joore M; Armstrong N; Ryder S; Stirk L; Severens J; Kleijnen J
    Health Technol Assess; 2015 Nov; 19(96):v-xxv, 1-236. PubMed ID: 26569153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients.
    Powell MZ; Mara KC; Bansal R; Hathcock MA; Khurana A; Bennani NN; Wang Y; Paludo J; Bisneto JV; Ansell SM; Johnston PB; Lin Y; Barreto JN
    Cancer Med; 2023 Apr; 12(8):9228-9235. PubMed ID: 36752185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of procalcitonin testing to a targeted audit-and-feedback strategy on prescribed durations of therapy for community-acquired pneumonia.
    Clark LT; Beuschel TS; Buss PM; Jameson AP; Dumkow LE
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115202. PubMed ID: 33007583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of procalcitonin on antimicrobial treatment decisions in patients with coronavirus disease 2019 (COVID-19).
    Conlon ASC; Chopra Z; Cahalan S; Cinti S; Rao K
    Infect Control Hosp Epidemiol; 2023 Aug; 44(8):1314-1320. PubMed ID: 36330692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.